

30 Nov 2018 | News

QUOTED. Nov. 30, 2018. Graham Mullis.

by

French diagnostics firm Novacyt made its second deal in recent months, to supply molecular assay panels to US-based Genesis Diagnostics. The company is intentionally pushing an aggressive deal strategy for 2018 to prepare for anticipated global-economy headwinds in 2019, CEO Graham Mullis explains here.

"In 2019, we expect Brexit to have a big impact on the market, and trade relations between US and China on the global economy, so these are things we are watching ... For now, we are working hard to get as many deals over the line before the end of the year." –Graham Mullis, CEO, Novacyt SA

- Find out more: [Novacyt Lands New US Supply Deal, Maps Path To Profitability](#)

[Click here](#) for a free trial of *Medtech Insight*